Freenome secures FDA nod for blood-based colorectal cancer test
Source ↗
👁 0
💬 0
Abbott will market Freenome’s SimpleScreen CRC test in the U.S., alongside its Cologuard stool test. SimpleScreen will compete with Guardant Health’s Shield blood test for colorectal cancer screening.
Comments (0)